이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pharmaniaga Berhad 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zulkifli Bin Jafar

최고 경영자

RM 168.6k

총 보상

CEO 급여 비율	83.1%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28

CEO 보상 분석

Zulkifli Bin Jafar 의 보수는 Pharmaniaga Berhad 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-RM 56m
Mar 31 2024	n/a	n/a	-RM 57m
Dec 31 2023	RM 169k	RM 140k	-RM 80m
Sep 30 2023	n/a	n/a	-RM 667m
Jun 30 2023	n/a	n/a	-RM 654m
Mar 31 2023	n/a	n/a	-RM 655m
Dec 31 2022	RM 1m	RM 800k	-RM 630m
Sep 30 2022	n/a	n/a	RM 100m
Jun 30 2022	n/a	n/a	RM 164m
Mar 31 2022	n/a	n/a	RM 177m
Dec 31 2021	RM 145k	n/a	RM 172m
Sep 30 2021	n/a	n/a	RM 80m
Jun 30 2021	n/a	n/a	RM 32m
Mar 31 2021	n/a	n/a	RM 28m
Dec 31 2020	RM 61k	n/a	RM 27m

보상 대 시장: Zulkifli 의 총 보상 ($USD 38.72K ) MY 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 108.28K ).

보상과 수익: Zulkifli 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Zulkifli Bin Jafar (52 yo)

less than a year

테뉴어

RM 168,569

보상

Encik Zulkifli Bin Jafar is the Managing Director at Pharmaniaga Berhad since September 1, 2024 and serves as its Deputy Chief Executive Officer since February 22, 2023 and was its Executive Director since...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zulkifli Bin Jafar	Deputy CEO & Managing Director	less than a year	RM 168.57k	데이터 없음
Norai'ni Binti Mohamed Ali	Chief Financial Officer	12.3yrs	데이터 없음	데이터 없음
Badarulhisam Rahman	Chief Scientific Officer	1.8yrs	데이터 없음	데이터 없음
Abdul Mohamed	Executive Vice President of Logistics & Distribution Division	no data	데이터 없음	데이터 없음
Zulhazri bin Razali	Executive Vice President of Commercial Division	no data	데이터 없음	데이터 없음
Wan Intan Wan Ismail	Executive VP of Corporate Governance & Company Secretary	4.9yrs	데이터 없음	데이터 없음
Azni Basri	Chief People Officer	less than a year	데이터 없음	데이터 없음
Idham Ismail	Chief Strategy Officer	no data	데이터 없음	데이터 없음
Mohd Ishak	Acting Head of Manufacturing Operations	less than a year	데이터 없음	데이터 없음
Fazleena Jasin	Head of Sustainability	no data	데이터 없음	데이터 없음
Syaruzaimi Yusof	Company Secretary	4.9yrs	데이터 없음	데이터 없음
Ahmad Bakar	President Director of PT Millennium Pharmacon International Tbk	4.3yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: PHARMA 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zulkifli Bin Jafar	Deputy CEO & Managing Director	less than a year	RM 168.57k	데이터 없음
Ahmad Bakar	President Director of PT Millennium Pharmacon International Tbk	4.3yrs	데이터 없음	데이터 없음
Yves Champey	Member of Board Advisory Panel	no data	데이터 없음	데이터 없음
Mary Cardosa	Independent & Non Executive Director	less than a year	RM 56.20k	데이터 없음
Izaddeen Bin Daud	Non-Independent Non-Executive Chairman	3.6yrs	RM 192.81k	데이터 없음
Mohd Bin Zahur Hussain	Independent Non Executive Director	less than a year	RM 40.00k	데이터 없음
V. Navaratnam	Member of Board Advisory Panel	no data	데이터 없음	데이터 없음
Musa bin Mohamad	Chairman of Board Advisory Panel	no data	데이터 없음	데이터 없음
Piero Olliaro	Member of Board Advisory Panel	no data	데이터 없음	데이터 없음
Sarah binti Abdul Samat	Independent & Non-Executive Director	3.2yrs	RM 181.67k	데이터 없음
Ahmad Shahredzuan Mohd Shariff	Non Independent & Non Executive Director	1.7yrs	RM 136.05k	데이터 없음
Abdul Bin Ahmad	Senior Independent & Non-Executive Director	3.9yrs	RM 190.04k	데이터 없음

2.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: PHARMA 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Pharmaniaga Berhad 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024

High number of new directors

Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

Recent updates

Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024

Second quarter 2024 earnings released

High number of new directors

New minor risk - Share price stability

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023)

Now 24% undervalued after recent price drop

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

New major risk - Revenue and earnings growth

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

New minor risk - Share price stability

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Price target decreased by 19% to RM0.28

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee

New minor risk - Shareholder dilution

New minor risk - Market cap size

Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding

Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021)

Price target decreased by 33% to RM0.41

Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021)

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

High number of new directors

Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd.

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021)

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director

Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Price target decreased to RM0.87

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Upcoming dividend of RM0.05 per share

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Consensus EPS estimates increase to RM0.09

Upcoming dividend of RM0.02 per share

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020)

Upcoming dividend of RM0.015 per share

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Independent Non-Executive Director Zainal Shariff has left the company

Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020)

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week